Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Block Listing Return

1 Oct 2025 07:00

RNS Number : 4666B
Cambridge Cognition Holdings PLC
01 October 2025
 

1 October 2025

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Listing Return

 

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

 

Name of applicant:

Cambridge Cognition Holdings plc

Name of scheme:

Share Options

Period of return:

From:

1 April 2025

To:

30 September 2025

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023

Balance of unallotted securities under scheme(s) from previous return:

466,316 ordinary shares

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

466,316 ordinary shares

 

Name of contact:

Simon McKeating

Telephone number of contact:

+44 (0)1223 810700

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Rob Baker, Senior Executive Director and Group Chief Operating Officer

 

Tel: 012 2381 0700 

press@camcog.com 

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Mark Rogers / Freddy Crossley

Rupert Dearden 

Tel: 020 7886 2968

(Corporate Finance)

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / Amber Higgs

 

Tel: 020 3903 7715 

 

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

· Clinical Studies for new pharmaceuticals;

· Academic Research for scientists to understand CNS disorders;

· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREALNEDEDSEFA
Date   Source Headline
14th Nov 20187:00 amRNSContract win in growing eCOA revenue stream
20th Sep 20187:00 amRNSHalf Yearly Report
19th Sep 20187:00 amRNSCompany signs first NeuroVocalix contract
13th Sep 20187:00 amRNSNeuroVocalixT platform ready for clinical trials
1st Aug 20187:00 amRNSCANTAB incorporated in population health platform
20th Jun 20187:00 amRNSNew product to improve workplace mental health
7th Jun 20187:00 amRNSPartnership to tackle growing mental health need
31st May 20187:00 amRNSNew client signs with Cognition Kit software
24th May 201812:24 pmRNSResult of AGM
9th May 201811:34 amRNSHolding(s) in Company
3rd May 20187:00 amRNSDirector/PDMR Shareholding
2nd May 20187:00 amRNSPosting of Annual Report & Notice of AGM
12th Apr 20181:20 pmRNSHolding(s) in Company
12th Apr 201810:20 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSRecruitment contracts show strong growth
26th Mar 20187:00 amRNSMajor Contract Win and Funding Award
22nd Mar 201811:05 amRNSSecond Price Monitoring Extn
22nd Mar 201811:00 amRNSPrice Monitoring Extension
22nd Mar 20187:00 amRNSFinal Results
1st Mar 20187:30 amRNSHolding(s) in Company
27th Feb 20184:25 pmRNSHolding(s) in Company
10th Jan 20187:00 amRNSTrading Update and Notice of Results
5th Dec 20178:55 amRNSHolding(s) in Company
28th Nov 20177:00 amRNSWearable technology demonstrates high compliance
2nd Nov 20177:00 amRNSGrant of Options
10th Oct 201711:00 amRNSHolding(s) in Company
10th Oct 201710:58 amRNSHolding(s) in Company
6th Oct 20177:00 amRNSIssue of Equity
21st Sep 20177:00 amRNSHalf-year Report
12th Sep 20177:00 amRNSAward of Funding
31st Aug 20177:00 amRNSNotice of Results
12th Jun 20179:56 amRNSHolding(s) in Company
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
7th Jun 20177:00 amRNSSpeech recognition for clinical trials
25th May 20172:22 pmRNSResult of AGM & Board Change
24th May 20174:27 pmRNSHolding(s) in Company
22nd May 20177:00 amRNSIssue of Equity
11th May 20171:07 pmRNSHolding(s) in Company
10th May 20177:00 amRNSGrant of Options
2nd May 20177:00 amRNSPosting of Annual Report & Notice of AGM
30th Mar 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSAnnual Financial Report
16th Mar 20177:00 amRNSCANTAB used in EBBINGHAUS cognitive function trial
7th Mar 20177:00 amRNSLaunch of web-based testing for virtual research
24th Feb 20177:00 amRNSPartnership With Takeda For Wearables
23rd Feb 20177:00 amRNSNotice of Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUS regulatory clearance for CANTAB Mobile
4th Nov 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSContract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.